Srini Tenjarla was named Chief Technology Officer of Serina Therapeutics, Inc. As of November 6, 2026, Serina Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to July 23, 2026, naming 1 appointment (Form 8-K, April 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Serina Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-23
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-22
- · In / out: In · Person: Srini Tenjarla · Role: Chief Technology Officer · 8-K, 2026-04-21
Serina Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-07-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Serina Therapeutics, Inc. files it.
Also on the record for Serina Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Sio Capital Management, LLC | 7.87% of the class | 5%+ stakes | Source |
| July 22, 2026 | Stake report, Schedule 13D/A, by Juvenescence Limited | 27.3% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G, by Sio Capital Management, LLC | 6.71% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Serina Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Serina Therapeutics, Inc. and the records around it.
Serina Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
Watch Serina Therapeutics, Inc.
Get an email when Serina Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Serina Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Serina Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Serina Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-23 | Reported | not named in the filing | 8-K, 2026-07-23 | ||
| 2026-07-22 | Reported | not named in the filing | 8-K, 2026-07-22 | ||
| 2026-04-21 | In | Chief Technology Officer | 8-K, 2026-04-21 |
Who leads Serina Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Technology Officer: Srini Tenjarla, appointed (filed 2026-04-21).
New leaders reset buying decisions — get the Full Report on Serina Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Technology Officer at Serina Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Technology Officer at Serina Therapeutics, Inc.Every change, in the filing's words
Reported
The A&R Employment Agreement also contains confidentiality, non-competition (two years following termination), non-solicitation and no-hire (18 months following termination), and non-disparagement covenants.
- On July 19, 2026, Serina Therapeutics, Inc. (the "Company"), together with its subsidiary Serina Therapeutics (AL), Inc., entered into an Amended and Restated Employment Agreement (the "A&R Employment Agreement") with Steve Ledger, the Company's Chief Executive Officer.
- The A&R Employment Agreement amends and restates in its entirety the Employment Agreement among the parties dated September 9, 2024.
- Under the A&R Employment Agreement, Mr. Ledger will receive an annual base salary of $500,000 and will be eligible for a target annual bonus equal to 50% of his base salary based on the achievement of annual goals established by the Board of Directors.
- The A&R Employment Agreement also reflects Mr. Ledger's previously granted stock options and provides that he remains eligible to receive additional equity awards in the discretion of the Board.
- The A&R Employment Agreement further provides that, in connection with any Change in Control, the Company will cause Mr. Ledger's outstanding equity awards to be assumed, continued, or substituted by the successor or surviving entity.
- Any payments or benefits that would constitute "parachute payments" under Section 280G of the Internal Revenue Code are subject to a "best-net" reduction, with no excise tax gross-up.
Reported
On July 22, 2026, Serina Therapeutics, Inc. (the "Company") issued a press release announcing the appointment of Farrell Simon, Pharm.
- D., to the Company's Board of Directors, effective July 22, 2026.
- Dr. Simon has also been appointed to serve as the a member of the Audit Committee and Compensation Committee Dr. Simon is a biotech, pharmaceutical and consumer health executive with expertise in commercial strategy, operations, and business development.
- He currently serves as Chief Commercial Officer at Trevi Therapeutics, Inc. (Nasdaq TRVI), where he leads commercial strategy, lifecycle management, and pre-commercial readiness planning.
- He also leads business development efforts for potential partnerships and M A. During his tenure at Trevi, he helped engage Trevi's investor base and supported financings totaling more than $400 million from top-tier investors including Frazier, Vivo, Venrock, and Viking.
- Prior to Trevi, Dr. Simon spent a decade at Pfizer in a series of senior commercial and strategic leadership roles, including Biopharma Chief of Staff and global commercial leadership positions supporting major brands and pipeline assets.
- He holds a Doctor of Pharmacy degree and an MBA, with a concentration in Finance, from the University of Florida.
- For serving on our Board of Directors, Dr. Simon will receive compensation in accordance with the Company's Director Compensation Policy.
Appointed: Srini Tenjarla, Chief Technology Officer
Chief Technology Officer On April 20, 2026, Serina Therapeutics (AL), Inc. (the " Serina (AL) "), a wholly owned subsidiary of Serina Therapeutics, Inc. (the " Company "), named Srini Tenjarla, Ph.D., its Chief Technology Officer.
- Dr. Tenjarla had previously served as Serina (AL)'s Senior Vice President of CMC and Formulation since July 2024.
- In connection with the promotion, Dr. Tenjarla's annual base salary was increased to $425,000, effective back to March 15, 2026.
- Chief Executive Officer Compensation On April 15, 2026, the Company increased the annual base salary of Steve Ledger, the Company's Chief Executive Officer, to $500,000.
- The increase in base salary was pursuant to Mr. Ledger's employment agreement upon the satisfaction of certain strategic goals, and is effective as of September 9, 2024, the date of Mr. Ledger's employment agreement.
- The Company has paid the retroactive portion of the base salary increase in a lump sum in April 2026.
Tools for this story
Each opens in a new tab, filled in for Serina Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.